Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

Recently, there has been increased concern about a risk of secondary malignancies (SM) occurring in myelofibrosis (MF) patients receiving ruxolitinib (RUX). In polycythemia vera (PV), on the other hand, only limited data on the risk of SM under RUX treatment are available. To investigate the associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekhri, Rohit, Sadjadian, Parvis, Becker, Tatjana, Kolatzki, Vera, Huenerbein, Karlo, Meixner, Raphael, Marchi, Hannah, Wallmann, Rudolf, Fuchs, Christiane, Griesshammer, Martin, Wille, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510903/
https://www.ncbi.nlm.nih.gov/pubmed/34462786
http://dx.doi.org/10.1007/s00277-021-04647-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510903/
https://www.ncbi.nlm.nih.gov/pubmed/34462786
http://dx.doi.org/10.1007/s00277-021-04647-0

Ejemplares similares